Loading...

COR CENCORA INC Investor Conferences 8-K Filing

CNCR

CR

CENCORA INC

(COR)

2024 8-K

Earnings Report Update

Credit Amendments

Legal Settlement Update

Leadership Transition

Financial Statements

Debt Restructuring

Amendments to Credit Facili...

Appointments, Resignations

Debt-Equity Swaps

Debt-Equity Swaps

Financial Statements

Shareholder Meeting

Conference Update

Share Repurchase

Earnings Announcement

Acquisition Completed

Senior Notes Offering

Acquisition Announcement

Earnings Announcement

Credit Facility Amendments

Performance Update

Management Changes

Director Appointment

Share Repurchase Agreement

Cybersecurity Incident

Earnings Reports

Share Repurchase Agreement

Securitization Facility Ame...

Amendment to Compensation A...

Amendment to Certificate of...

Appointment of CEO

Cybersecurity Incident

Share Repurchase Agreement

Sale of Senior Notes

Underwriting Agreement for ...

Departure of Director

Bylaws Amendment

Stock Trading Plan Adoption

Share Repurchase Agreement

Earnings Reports

Amended Credit Agreement

Board Appointments

Share Repurchase

Earnings Release & Name Change

Share Repurchase Agreement

Acquisition of OneOncology

Share Repurchase Agreement

Amendment of Securitization...

Earnings Report

Acquisition of OneOncology

Annual Meeting of Shareholders

Departure of Directors

External Links:

Cencora, Inc. executives will present updates on performance expectations, with adjusted diluted EPS for fiscal year 2024 now expected to be between $13.60 and $13.70, and they have extended a pharmaceutical supply agreement with Evernorth Health Services through September 2029.

AI Assistant

CENCORA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.